Daily Anesthesiology Research Analysis
Analyzed 23 papers and selected 3 impactful papers.
Summary
Today’s most impactful studies in anesthesiology and pain medicine include: (1) a randomized non-inferiority trial showing opioid-free anesthesia preserves recovery quality and halves PONV after laparoscopic hysterectomy; (2) a large perioperative cohort with machine-learning predicting new-onset postoperative heart block and its phase-specific mortality risks; and (3) a double-blind RCT indicating lacosamide is comparable to propranolol for episodic migraine prevention.
Research Themes
- Opioid-sparing anesthesia and postoperative recovery
- Perioperative cardiac conduction complications and risk prediction
- Migraine prevention strategies in pain medicine
Selected Articles
1. Opioid-Free Versus Opioid-Based Anesthesia for Quality of Recovery Following Laparoscopic Hysterectomy: A Randomized Controlled Non-Inferiority Trial.
In 110 women undergoing laparoscopic hysterectomy, opioid-free anesthesia achieved non-inferior 24-hour QoR-15 scores versus opioid-based anesthesia and halved PONV incidence and severity, with similar postoperative morphine use and no serious adverse events. Results support opioid-free protocols as effective alternatives, especially for patients at high PONV risk.
Impact: Provides randomized evidence that opioid-free anesthesia maintains recovery quality while reducing PONV, addressing a key patient-centered outcome and safety concern.
Clinical Implications: Adopt opioid-free anesthesia protocols (e.g., dexmedetomidine/esketamine with volatile maintenance) for laparoscopic hysterectomy, particularly in patients at high risk of PONV, while monitoring for comparable analgesia needs.
Key Findings
- Opioid-free anesthesia was non-inferior for 24-hour QoR-15 (median difference 2.0; 95% CI -1.0 to 4.0; p<0.001 for non-inferiority).
- PONV incidence was reduced (18.2% vs 36.4%; RR 0.50, 95% CI 0.26-0.97; p=0.032) and severity decreased (OR 0.39, 95% CI 0.16-0.94; p=0.035).
- Postoperative morphine consumption was similar (8 mg vs 10 mg; p=0.315) and no serious adverse events occurred.
Methodological Strengths
- Randomized non-inferiority trial with prospective registration and predefined margin.
- Blinded outcome assessment/standardized QoR-15 and high protocol adherence (96%).
Limitations
- Single-procedure, ASA I–II female cohort limits generalizability to higher-risk populations and other surgeries.
- Sample size may be underpowered for rare adverse events or subgroup effects.
Future Directions: Multicenter trials across diverse surgeries and risk profiles, evaluation of long-term analgesic use, recovery trajectories, and cost-effectiveness of opioid-free anesthesia.
BACKGROUND: Laparoscopic gynecological surgery traditionally relies on opioids for general anesthesia, yet these medications frequently cause postoperative nausea and vomiting (PONV), respiratory depression, and delayed recovery. This randomized trial evaluated whether opioid-free anesthesia maintains recovery quality while reducing complications in women undergoing laparoscopic hysterectomy. METHODS: We randomized 110 women (American Society of Anesthesiologists physical status I-II) undergoing elective laparoscopic hysterectomy to receive either opioid-free anesthesia (dexmedetomidine/esketamine induction; dexmedetomidine/sevoflurane maintenance) or opioid-based anesthesia (sufentanil induction; remifentanil/ sevoflurane maintenance). The primary outcome was recovery quality at 24 hours, measured using the Quality of Recovery-15 (QoR-15) questionnaire. Non-inferiority was defined as a between-group difference of less than 6 points. Secondary outcomes included pain scores, morphine consumption, PONV, and adverse events. RESULTS: All 110 patients completed follow-up with 96% protocol adherence. The opioid-free group demonstrated non-inferior QoR-15 scores: median 123 (IQR 115-127) versus 121 (IQR 114-125) for opioid-based anesthesia, with a 2.0-point median difference (95% CI -1.0 to 4.0, p < 0.001). Postoperative morphine consumption was comparable between groups (8 mg [IQR 8-12] vs. 10 mg [IQR 8-12], median difference p = 0.315). The opioid-free group exhibited reduced PONV incidence (10/55 [18.2%] vs. 20/55 [36.4%]; relative risk 0.50, 95% CI 0.26-0.97, p=0.032) and severity (odds ratio 0.39, 95% CI 0.16 to 0.94, p = 0.035). No serious adverse events occurred. CONCLUSION: Opioid-free anesthesia demonstrated non-inferiority to opioid-based anesthesia for recovery quality while reducing the incidence and severity of PONV. These findings support opioid-free protocols as effective alternatives for laparoscopic hysterectomy, particularly for patients at high PONV risk. REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2300071297).
2. Lacosamide Versus Propranolol in Episodic Migraine, a Randomized Controlled Double-blinded Trial.
In a double-blind RCT (n=574), lacosamide (50 mg BID) achieved reductions in monthly migraine days, need for acute medications, and HIT-6 scores comparable to propranolol (80 mg BID) over 3 months, with good tolerability. No significant between-group differences were detected across key outcomes.
Impact: Provides randomized, blinded evidence that lacosamide is a viable alternative to propranolol for migraine prevention, expanding options for patients intolerant to beta-blockers.
Clinical Implications: For patients who cannot tolerate propranolol, lacosamide may be considered as an alternative preventive agent with comparable efficacy over 3 months and favorable tolerability.
Key Findings
- No significant between-group difference in reduction of monthly migraine days (P=0.13).
- Responder rate (>50% reduction in migraine days) did not differ (P=0.22).
- Reduction in monthly migraine days requiring acute medication and HIT-6 score were comparable (P=0.57 and P=0.61).
- Lacosamide 50 mg BID was well tolerated over 3 months.
Methodological Strengths
- Randomized, double-blind design with adequate sample size (n=574).
- Registered trial with standardized outcome measures (MMD, HIT-6).
Limitations
- Follow-up limited to 3 months; long-term durability and rare adverse events not assessed.
- Fixed dosing without dose-ranging; no head-to-head comparison with CGRP-targeted preventives.
Future Directions: Longer-term, dose-ranging RCTs and head-to-head comparisons with CGRP monoclonal antibodies and topiramate; evaluation in special populations (e.g., cardiovascular comorbidity).
Although migraine is the second most prevalent form of headache, its preventive treatment has some contraindications and complications. It has been postulated that lacosamide might inhibit CGRP release in the trigeminal system, which could contribute to migraine management. We aimed to evaluate the efficacy and safety of lacosamide as an alternative medication to propranolol for preventing episodic migraine, especially in patients who cannot tolerate propranolol and approved antiseizure medicines for migraine prevention. We recruited patients with episodic migraines; we had two groups: lacosamide group who received lacosamide 50 mg once daily for 1 week, then twice daily from the 8th day till the 90th day; propranolol group who received propranolol 40 mg twice daily for 1 week, then 80 mg twice daily from the 8th till the 90th day. 574 completed the study. In episodic migraine patients, there was no significant difference in the MMD in the last 4 weeks of treatment compared to baseline, the percentage of patients who achieved > 50% reduction in migraine days, reduction in MMD that required acute medication in the last 4 weeks, reduction in HIT score compared to baseline in both groups with P-values 0.13, 0.22, 0.57, and 0.61 respectively. In episodic migraine patients, the regular use of lacosamide 50 mg Bid for 3 months yielded reductions in the monthly migraine days, migraine days that required acute medications, and HIT6 score comparable to those achieved using propranolol 80mg Bid. Lacosamide was well-tolerated by migraine patients. Trial registration: registered on clinicaltrial.gov, NCT05851781-30/04/2023.
3. Postoperative New-Onset Heart Block in Noncardiac Surgery: Model Development, Validation, and Long-Term Prognostic Analysis.
Among 281,497 noncardiac surgeries, new-onset heart block occurred in 0.36%. An XGBoost model using 12 predictors achieved AUC 0.804. Atrioventricular block strongly predicted early-phase mortality, whereas right bundle branch block was associated with late-phase mortality, highlighting the need for enhanced perioperative surveillance.
Impact: Defines incidence and prognostic heterogeneity of postoperative heart block at scale and provides a high-performing predictive model to target surveillance and interventions.
Clinical Implications: Implement risk prediction and focused monitoring for new-onset conduction disturbances after noncardiac surgery, particularly prioritizing early evaluation for AV block and longitudinal follow-up for RBBB.
Key Findings
- Incidence of postoperative new-onset heart block was 0.36% (1,000/281,497).
- XGBoost model with 12 predictors achieved validation AUC 0.804.
- Atrioventricular block predicted poor early-phase prognosis (adjusted HR 6.24), while RBBB associated with poor late-phase prognosis (adjusted HR 2.67).
Methodological Strengths
- Very large cohort enabling precise incidence estimates and robust modeling.
- Use of LASSO for feature selection, multiple ML algorithms, and piecewise Cox regression for phase-specific risk.
Limitations
- Retrospective, single-system EHR analysis susceptible to coding/misclassification and residual confounding.
- External validation and impact of model-guided interventions were not assessed.
Future Directions: External validation across health systems, integration into perioperative decision support, and interventional studies testing surveillance or pacing strategies guided by predicted risk.
BACKGROUND: Heart block is common in cardiac surgery but understudied in noncardiac settings despite its poor prognosis. OBJECTIVES: This study aims to investigate epidemiology, develop predictive models, and assess the prognostic value of new-onset heart block after noncardiac surgery. METHODS: This retrospective study analyzed 281,497 patients from 2008 to 2019. The primary outcome was new-onset heart block within 30 days. We used least absolute shrinkage and selection operator for variable selection and machine learning algorithms (eg, Nnet, LGBM, SVM, and XGB) for prediction. Piecewise Cox regression was used to analyze 1-year survival in elderly patients. RESULTS: New-onset heart block occurred in 1,000 of 281,497 patients (0.36%; 95% CI: 0.33%-0.38%). Subtypes included 192 of 281,497 atrioventricular (AV) blocks (0.07%; 95% CI: 0.06%-0.08%); 51 of 281,497 left bundle branch blocks (0.02%; 95% CI: 0.01%-